PE20010152A1 - Derivados heterociclicos utiles como agentes anticancerosos - Google Patents

Derivados heterociclicos utiles como agentes anticancerosos

Info

Publication number
PE20010152A1
PE20010152A1 PE2000000458A PE0004582000A PE20010152A1 PE 20010152 A1 PE20010152 A1 PE 20010152A1 PE 2000000458 A PE2000000458 A PE 2000000458A PE 0004582000 A PE0004582000 A PE 0004582000A PE 20010152 A1 PE20010152 A1 PE 20010152A1
Authority
PE
Peru
Prior art keywords
alkyl
conr5r6
members
aryl
cancer agents
Prior art date
Application number
PE2000000458A
Other languages
English (en)
Inventor
Mark Carl Noe
Thomas George Gant
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010152A1 publication Critical patent/PE20010152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE ISOTIAZOL DE FORMULA I, DONDE Z: ES S, O, NR6; X ES N, CR4; X1 ES O, S, SO, SO2, NR6, CR5R6; R ES -CONR5R6, -CO2R5, -NR5R6, ENTRE OTROS; R1 ES H, ALQUILO C1-C10, -(CH2)t(ARILO C6-C10), ENTRE OTROS; t ES 0-5; R2 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, -C(O)(ALQUILO C1-C10), ENTRE OTROS; R3 ES -CR5R6R7, SO2R5, -CONR5R6; R4 ES H, ALQUILO C1-C6 Y JUNTO CON X1 O R1 FORMAN UN ANILLO DE 5-6 MIEMBROS, HETEROARILO DE 5-6 MIEMBROS CON 1 A 3 O, S Y NR6; R5 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, -C(O)(ALQUILO C1-C10), (CH2)t(ARILO C6-C10), ENTRE OTROS; R6 ES R5, -SO2(CH2)t(ARILO C6-C10), ENTRE OTROS; R7 ES H, ALQUILO C1-C10, ALQUENILO C2-C10, CO-ALQUILO C1-C10, ENTRE OTROS; O R5 Y R6 JUNTO CON N FORMAN UN MONOCICLO O POLICICLO DE 4-10 MIEMBROS, HETEROARILO DE 5-10 MIEMBROS; CUANDO X1 ES O, Z NO ES S; X NO ES N; R NO ES CONH2; R2 NO ES H; R3 NO ES CONR5R6; CUANDO X1 ES S, Z NO ES S, X NO ES N; R NO ES CONH2, R2 NO ES H; R3 NO ES CONR5R6. SON COMPUESTOS PREFERIDOS AMIDA DEL ACIDO 2-(3,3-DIMETIL-UREIDO)-4-PROPOXI-TIOFEN-3-CARBOXILICO; AMIDA DEL ACIDO 4-BUTOXI-2-(3,3-DIMETIL-UREIDO)-TIOFEN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS INHIBIDORES MITOTICOS, AGENTES ALQUILANTES, ANTI-METABOLITOS, ENTRE OTROS. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER
PE2000000458A 1999-05-19 2000-05-16 Derivados heterociclicos utiles como agentes anticancerosos PE20010152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13493399P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
PE20010152A1 true PE20010152A1 (es) 2001-02-08

Family

ID=22465672

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000458A PE20010152A1 (es) 1999-05-19 2000-05-16 Derivados heterociclicos utiles como agentes anticancerosos

Country Status (21)

Country Link
US (1) US6380214B1 (es)
EP (1) EP1187826B1 (es)
JP (2) JP3692041B2 (es)
AR (1) AR029634A1 (es)
AT (1) ATE349440T1 (es)
AU (1) AU4137400A (es)
BR (1) BR0010746A (es)
CA (1) CA2374247C (es)
CO (1) CO5170417A1 (es)
DE (1) DE60032601T2 (es)
DZ (1) DZ3042A1 (es)
ES (1) ES2276681T3 (es)
GT (1) GT200000069A (es)
HN (1) HN2000000051A (es)
MA (1) MA26733A1 (es)
MX (1) MXPA01011920A (es)
PA (1) PA8494101A1 (es)
PE (1) PE20010152A1 (es)
TN (1) TNSN00104A1 (es)
UY (1) UY26143A1 (es)
WO (1) WO2000071532A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1268472B1 (en) 2000-02-07 2004-10-13 Bristol-Myers Squibb Company 3-aminopyrazole inhibitors of cyclin dependent kinases
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
US20070060551A1 (en) * 2002-06-13 2007-03-15 Qlt, Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
CN101721412A (zh) * 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
CN101602756B (zh) * 2002-07-09 2014-11-12 法斯根公司 化合物、含该化合物的药物组合物以及该化合物的应用方法
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
AU2003302665B2 (en) * 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US7534802B2 (en) * 2003-03-07 2009-05-19 Santen Pharmaceutical Co., Ltd. Compounds having 4-pyridylalkylthio group as substituent
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
CN1918127B (zh) * 2004-02-17 2012-02-15 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的环状化合物
ATE512950T1 (de) * 2004-02-17 2011-07-15 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
JP5100390B2 (ja) * 2004-08-26 2012-12-19 ファイザー・インク イソチアゾール誘導体の製造方法
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
EP1879879B1 (en) * 2005-05-13 2013-03-27 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
SI2104674T1 (sl) 2006-11-15 2013-09-30 Vertex Pharmaceuticals (Canada) Incorporated Tiofenski analogi za zdravljenje ali preprečevanje flavivirusnih infekcij
DK2116530T3 (da) 2007-02-26 2013-01-28 Santen Pharmaceutical Co Ltd Nyt pyrrolderivat, der har en ureidgruppe og en aminobonylgruppe som substituenter
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
US8748453B2 (en) * 2009-06-25 2014-06-10 Medolution Limited Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof
AU2013205240B2 (en) 2012-03-16 2016-02-11 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
NZ733950A (en) 2014-12-23 2018-08-31 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1950990A1 (de) * 1968-10-17 1970-05-14 Ciba Geigy Verfahren zur Herstellung von neuen triazacyclischen Verbindungen
GB1355513A (en) * 1971-04-07 1974-06-05 May & Baker Ltd Isothiazole derivatives
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
US4075001A (en) * 1976-06-18 1978-02-21 Fmc Corporation 3-Aminoisothiazole derivatives as herbicides
US4057416A (en) * 1976-06-18 1977-11-08 Fmc Corporation 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides
DE3529247A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
DE3540377A1 (de) * 1985-11-14 1987-05-21 Bayer Ag Thienooxazinone, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer
DE3541631A1 (de) * 1985-11-26 1987-05-27 Bayer Ag Selektiv-fungizide verwendung von thienylharnstoff-derivaten
US4859699A (en) * 1987-07-20 1989-08-22 Sandoz Ltd. Substituted N-benzoyl-N'-thienylureas
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
AU700964B2 (en) * 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5792767A (en) * 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
CA2291065C (en) * 1997-05-23 2010-02-09 Bayer Corporation Raf kinase inhibitors
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
UY26143A1 (es) 2000-12-29
EP1187826B1 (en) 2006-12-27
US6380214B1 (en) 2002-04-30
JP2003500401A (ja) 2003-01-07
CO5170417A1 (es) 2002-06-27
ATE349440T1 (de) 2007-01-15
EP1187826A1 (en) 2002-03-20
BR0010746A (pt) 2002-02-13
MA26733A1 (fr) 2004-12-20
GT200000069A (es) 2001-11-08
MXPA01011920A (es) 2002-05-06
CA2374247A1 (en) 2000-11-30
ES2276681T3 (es) 2007-07-01
WO2000071532A1 (en) 2000-11-30
JP2005008641A (ja) 2005-01-13
DE60032601T2 (de) 2007-11-15
JP3692041B2 (ja) 2005-09-07
HN2000000051A (es) 2001-02-02
DE60032601D1 (de) 2007-02-08
AR029634A1 (es) 2003-07-10
AU4137400A (en) 2000-12-12
PA8494101A1 (es) 2003-09-05
DZ3042A1 (fr) 2004-03-27
TNSN00104A1 (fr) 2005-11-10
CA2374247C (en) 2008-01-22

Similar Documents

Publication Publication Date Title
PE20010152A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
FR2697524B1 (fr) Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
PT799833E (pt) Novos derivados da eritromicina, seu processo de preparacao e sua aplicacao como medicamentos
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
EA200100487A1 (ru) Производные 2-аминотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR035548A1 (es) Compuestos organicos
FI863564A0 (fi) Foerfarande foer framstaellning av heterocykliskt substituerade indoler.
HUP0401855A2 (hu) Pirimidin-származékok mint az inzulinszerű növekedési faktor-1 receptor (IGF-1R) modulátorai, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
CO6180449A2 (es) Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis
AR042706A1 (es) Compuestos (2-carboxamido)(3-amino) tiofenos y su uso para el tratamiento del cancer
HUP0101793A2 (hu) Antranilsav-származékok, mint cGMP-foszfodiészteráz gátlók
PE20070495A1 (es) COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
HUP0203787A2 (hu) Hidroxi-acetil-piperazinnal szubsztituált oxazolidinon-benzoesav-észterek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2262504T3 (es) Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
KR950704325A (ko) 류코트리엔 길항제로서의 디아릴 5,6-융합된 헤테로사이클릭산(Diaryl 5,6-fusesheterocyclic acids as leukotriene antagonists)
CO5580804A2 (es) Derivados de diazepanes utiles como inhibidores de lfa
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드

Legal Events

Date Code Title Description
FC Refusal